Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 1;215(9):1362-1365.
doi: 10.1093/infdis/jix089.

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa

Andrew N Phillips  1 , John Stover  2 , Valentina Cambiano  1 , Fumiyo Nakagawa  1 , Michael R Jordan  3 , Deenan Pillay  4 , Meg Doherty  5 , Paul Revill  6 , Silvia Bertagnolio  5
Affiliations

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa

Andrew N Phillips et al. J Infect Dis. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Infect Dis. 2017 Nov 15;216(8):1048. doi: 10.1093/infdis/jix440. J Infect Dis. 2017. PMID: 29149342 Free PMC article. No abstract available.

Abstract

To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub-Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.

Keywords: mathematical model.; HIV; cost; death; drug resistance; incidence.

PubMed Disclaimer

References

    1. UNAIDS. Global gains made towards the 90–90–90 targets 2016. http://www.unaids.org/en/resources/presscentre/featurestories/2016/july/... Accessed 4 May 2017.
    1. WHO. WHO HIV drug resistance report 2012. ISBN: 978 92 4 150393 8 http://www.who.int/hiv/pub/drugresistance/report2012/en/ Accessed 4 May 2017.
    1. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250–8. - PMC - PubMed
    1. Hamers RL, Schuurman R, Sigaloff KC, et al. ; PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307–17. - PubMed
    1. Wittkop L, Günthard HF, de Wolf F, et al. ; EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363–71. - PubMed

Substances